Luvox CR and Mexitil
Determining the interaction of Luvox CR and Mexitil and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using mexiletine together with fluvoxaMINE may increase the effects of mexiletine. Contact your doctor if you experience nausea, seizures, numbness or tingling, tiredness, dizziness, a loss of consciousness, and a worsening irregular heartbeat. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with fluvoxamine may increase the serum concentrations of mexiletine. The proposed mechanism is decreased clearance of mexiletine due to inhibition of the CYP450 1A2 and possibly 2D6 isoenzymes by fluvoxamine. In a randomized, crossover study consisting of six healthy subjects, fluvoxamine (50 mg orally twice a day for 7 days) increased the peak serum concentration (Cmax) and area under the concentration-time curve (AUC) of a single dose of mexiletine (200 mg) by 16% and 55%, respectively. The oral clearance decreased by 38%.
MANAGEMENT: Caution is advised during concomitant therapy with fluvoxamine and mexiletine. Serum mexiletine levels and electrocardiographic readings should be monitored closely and the dosage adjusted accordingly, particularly following initiation or discontinuation of fluvoxamine in patients who are stabilized on their antiarrhythmic regimen.
- Kusumoto M, Ueno K, Oda A, Takeda K, Mashimo K, Takaya K, Fujimura Y, Nishihori T, Tanaka K "Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men." Clin Pharmacol Ther 69 (2001): 104-7
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Luvox CR-MG 217 Topical
- Luvox CR-MG Plus Protein
- Luvox CR-MG217 Medicated Tar
- Luvox CR-Mg217 Sal-Acid Topical
- Luvox CR-Mi-Acid
- Luvox CR-Mi-Acid Double Strength
- Mexitil-Luxiq
- Mexitil-Lybrel
- Mexitil-Lyderm
- Mexitil-Lydia E. Pinkham
- Mexitil-Lyme disease vaccine (recombinant ospa) Intramuscular
- Mexitil-Lymepak